Thermosensitive gel containing cellulose acetate phthalate-efavirenz combination nanoparticles for prevention of HIV-1 infection

Journal of Biomedical Nanotechnology

Volumn 11, Issue 3, 2015, Pages 416-427

  Date, Abhijit A ^a   Shibata, Annemarie ^a   McMullen, Emily ^a   La Bruzzo, Krista ^a   Bruck, Patrick ^b   Belshan, Michael ^b   Zhou, You ^c   Destache, Christopher J ^a  

^a CREIGHTON UNIVERSITY   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Cellulose acetate phthalate; Efavirenz; HIV prophylaxis; Nanoparticles; Pluronic; Thermosensitive gel

Indexed keywords

CYTOLOGY; ENCAPSULATION; ESTERS; NANOPARTICLES; PARTICLE SIZE; VOLATILE FATTY ACIDS;

CELLULOSE ACETATE PHTHALATE; EFAVIRENZ; HIV PROPHYLAXIS; PLURONICS; THERMO-SENSITIVE GELS;

CELLULOSE;

CELLACEFATE; EFAVIRENZ; NANOPARTICLE; PHTHALIC ACID; ANTIVIRUS AGENT; BENZOXAZINE DERIVATIVE; CELLULOSE; DELAYED RELEASE FORMULATION; GEL; NANOCAPSULE;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENCAPSULATION; FEMALE; GEL; HEAT SENSITIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; NONHUMAN; PARTICLE SIZE; PRECIPITATION; PROPHYLAXIS; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; DRUG EFFECTS; HELA CELL LINE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; SYNTHESIS; TEMPERATURE; ULTRASTRUCTURE;

ANTIVIRAL AGENTS; BENZOXAZINES; CELL PROLIFERATION; CELLULOSE; DELAYED-ACTION PREPARATIONS; DIFFUSION; GELS; HELA CELLS; HIV INFECTIONS; HIV-1; HUMANS; NANOCAPSULES; PARTICLE SIZE; TEMPERATURE;

EID: 84918502614     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.1942     Document Type: Article

References (37)

1. http://www.unaids.org/en/media/unaids/contentassets/documents/document/2013/GARPR-2013-guidelines-en.pdf (accessed on September 11 (2013)).
2. http://www. amfar.org/about-hiv-And-Aids/facts-And-stats/statistics-worldwide/(accessed on September 11, (2013)).
3. G. C. Morris and C. J. Lacey, Microbicides and HIV prevention: Lessons from the past, looking to the future. Curr. Opin. Infect. Dis. 23, 57 (2010).
4. C. G. Kelly and R. J. Shattock, Specific microbicides in the prevention of HIV infection. J. Intern. Med. 270, 509 (2011).
5. D. R. Friend, Pharmaceutical development of microbicide drug products. Pharm. Dev. Technol. 15, 562 (2010).
6. V. Pirrone, B. Wigdahl, and F. C. Krebs, The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res. 90, 168 (2011).
7. Q. Abdool Karim, S. S. Abdool Karim, J. A. Frohlich, A. C. Grobler, C. Baxter, L. E. Mansoor, A. B. Kharsany, S. Sibeko, K. P. Mlisana, Z. Omar, T. N. Gengiah, S. Maarschalk, N. Arulappan, M. Mlotshwa, L. Morris, and D. Taylor, Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168 (2010).
8. A. Van Der Straten, L. van Damme, J. E. Haberer, and D. R. Bangsberg, Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 26, F13-F9 (2012).
9. J. Kenney, R. Singer, N. Derby, M. Aravantinou, C. J. Abraham, R. Menon, S. Seidor, S. Zhang, A. Gettie, J. Blanchard, M. Piatak Jr., J. D. Lifson, J. A. Fernández-Romero, T. M. Zydowsky, and M. Robbiani, A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use. AIDS Res. Hum. Retroviruses 28, 1476 (2012).
10. S. M. Fetherston, P. Boyd, C. F. McCoy, M. C. McBride, K. L. Edwards, S. Ampofo, and R. K. Malcolm, A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. Eur. J. Pharm Sci. 48, 406 (2012).
11. R. C. Rowe, P. J. Sheskey, and M. Quinn, (eds.), The Handbook of Pharmaceutical Excipients, Pharmaceutical Press, London (2009), pp. 143-145.
12. http://www. eastman.com/Literature-enter/P/PCI104.pdf (accessed on September 11 (2013)).
13. A. R. Neurath, N. Strick, Y. Y. Li, K. Lin, and S. Jiang, Design of a "microbicide" for prevention of sexually transmitted diseases using "inactive" pharmaceutical excipients. Biologicals 27, 11 (1999).
14. A. R. Neurath, N. Strick, Y. Y. Li, and A. K. Debnath, Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect. Dis. 1, 17 (2001).
15. A. R. Neurath, N. Strick, Y. Y. Li, S. Jiang, and A. K. Debnath, Anti-HIV-1 activity of cellulose acetate phthalate: Synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. BMC Infect. Dis. 2, 6 (2002).
16. A. R. Neurath, N. Strick, and Y. Y. Li, Anti-HIV-1 activity of anionic polymers: A comparative study of candidate microbicides. BMC Infect. Dis. 2, 27 (2002).
17. K. H. Manson, M. S. Wyand, C. Miller, and A. R. Neurath, Effect of a cellulose acetate phthalate topical cream on vaginal transmission of simian immunodeficiency virus in rhesus monkeys. Antimicrob. Agents Chemother. 44, 3199 (2000).
18. R. A. Otten, D. R. Adams, C. N. Kim, E. Jackson, J. K. Pullium, K. Lee, L. A. Grohskopf, M. Monsour, S. Butera, and T. M. Folks, Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: Strategy to study HIV preclinical interventions in nonhuman primates. J. Infect. Dis. 191, 164 (2005).
19. C. N. Kim, D. R. Adams, S. Bashirian, S. Butera, T. M. Folks, and R. A. Otten, Repetitive exposures with simian/human immunodeficiency viruses: Strategy to study HIV pre-clinical interventions in non-human primates. J. Med. Primatol. 35, 210 (2006).
20. C. J. Lacey, S. Woodhall, Z. Qi, S. Sawant, M. Cowen, S. McCormack, and S. Jiang, Unacceptable side-effects associated with a hyperosmolar vaginal microbicide in a phase 1 trial. Int. J. STD. AIDS. 21, 714 (2010).
21. A. A. Date and C. J. Destache, A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials 34, 6202 (2013).
22. R. Mehendale, M. Joshi, and V. B. Patravale, Nanomedicines for treatment of viral diseases. Crit. Rev. Ther. Drug Carrier Syst. 30, 1 (2013).
23. C. R. Cohen, J. Brown, A. B. Moscicki, E. A. Bukusi, J. R. Paull, C. F. Price, and S. Shiboski, A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days. PLoS One 6, e16258 (2011).
24. C. F. Price, D. Tyssen, S. Sonza, A. Davie, S. Evans, G. R. Lewis, S. Xia, T. Spelman, P. Hodsman, T. R. Moench, A. Humberstone, J. R. Paull, and G. Tachedjian, SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One 6, e24095 (2011).
25. C. J. Destache, T. Belgum, K. Christensen, A. Shibata, A. Sharma, and A. Dash, Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect. Dis. 9, 198 (2009).
26. A. A. Date, A. Shibata, M. Goede, B. Sanford, K. La Bruzzo, M. Belshan, and C. J. Destache, Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis. Antiviral Res. 96, 430 (2012).
27. S. Liu, H. Lu, A. R. Neurath, and S. Jiang. Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. Antimicrob. Agents Chemother. 49, 1830 (2005).
28. F. Maggiolo, Efavirenz: A decade of clinical experience in the treatment of HIV. J. Antimicrob. Chemother. 64, 910 (2009).
29. M. B. Maurin, S. M. Rowe, K. Blom, and M. E. Pierce, Kinetics and mechanism of hydrolysis of efavirenz. Pharm. Res. 19, 517 (2002).
30. E. Piñón-Segundo, A. Ganem-Quintanar, V. Alonso-Pérez, and D. Quintanar-Guerrero, Preparation and characterization of triclosan nanoparticles for periodontal treatment. Int. J. Pharm. 294, 217 (2005).
31. S. Pillay, V. Pillay, Y. E. Choonara, D. Naidoo, R. A. Khan, L. C. du Toit, V. M. Ndesendo, G. Modi, M. P. Danckwerts, and S. E. Iyuke, Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain. Int. J. Pharm. 382, 277 (2009).
32. M. Yang, S. K. Lai, Y. Y. Wang, W. Zhong, C. Happe, M. Zhang, J. Fu, and J. Hanes, Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew. Chem. Int. Ed. Engl. 50, 2597 (2011).
33. L. M. Ensign, B. C. Tang, Y. Y. Wang, T. A. Tse, T. Hoen, R. Cone, and J. Hanes, Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci. Transl. Med. 4, 138ra79 (2012).
34. F. M. Farin, L. G. Bigler, D. Oda, J. K. McDougall, and C. J. Omiecinski, Expression of cytochrome P450 and microsomal epoxide hydrolase in cervical and oral epithelial cells immortalized by human papillomavirus type 16 E6/E7 genes. Carcinogenesis 16, 1391 (1995).
35. A. V. Albright, S. Erickson-Viitanen, M. O'Connor, I. Frank, M. M. Rayner, and F. González-Scarano, Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of hiv type 1 replication in microglia in vitro. AIDS Res. Hum. Retroviruses 16, 1527 (2000).
36. B. M. Best, P. P. Koopmans, S. L. Letendre, E. V. Capparelli, S. S. Rossi, D. B. Clifford, A. C. Collier, B. B. Gelman, G. Mbeo, J. A. McCutchan, D. M. Simpson, R. Haubrich, R. Ellis, and I. Grant, Efavirenz concentrations in CSF exceed IC50 for wild-Type HIV. J. Antimicrob. Chemother. 66, 354 (2011).
37. C. Huang, S. J. Soenen, E. van Gulck, G. Vanham, J. Rejman, S. Van Calenbergh, C. Vervaet, T. Coenye, H. Verstraelen, M. Temmerman, J. Demeester, and S. C. De Smedt, Electrospun cellulose acetate phthalate fibers for semen induced anti-HIV vaginal drug delivery. Biomaterials 33, 962 (2012).